<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01356589</url>
  </required_header>
  <id_info>
    <org_study_id>ML25289</org_study_id>
    <nct_id>NCT01356589</nct_id>
  </id_info>
  <brief_title>A Study of MIRCERA for the Intrapetient Variability of Hemoglobin Levels in Patients With Chronic Renal Anemia (RIVAL)</brief_title>
  <official_title>Retrospective Study on Intrapatient VAriabiLity of the Hemoglobin Levels in Anemic CKD Patients in Predialysis (Stage 3-4) and Dialysis (Stage 5) Treated With MIRCERAÂ® (RIVAL Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This retrospective observational study will assess the incidence of hemoglobin cycling in
      chronic kidney disease (stage 3, 4, and 5) patients with renal anemia treated with Mircera
      (methoxy polyethylene glycol-epoetin beta). Data will be collected from each patient from a
      9-month treatment period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 30, 2010</start_date>
  <completion_date type="Actual">July 31, 2012</completion_date>
  <primary_completion_date type="Actual">July 31, 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With at Least One Hemoglobin Cycling</measure>
    <time_frame>9 months</time_frame>
    <description>Hemoglobin cycling was defined as 1 or more cycles of oscillation in hemoglobin with an amplitude of greater than or equal to (&gt;=) 1.5 gram per deciliter (g/dL) and a duration &gt;=8 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Full Hemoglobin Cycles Per Participant</measure>
    <time_frame>9 months</time_frame>
    <description>Hemoglobin cycling was defined as 1 or more cycles of oscillation in hemoglobin with an amplitude of &gt;=1.5 g/dL and a duration &gt;=8 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Type 2 Diabetes Who Experienced at Least 1 Hemoglobin Cycling</measure>
    <time_frame>9 months</time_frame>
    <description>Hemoglobin cycling was defined as 1 or more cycles of oscillation in hemoglobin with an amplitude of &gt;=1.5 g/dL and a duration &gt;=8 weeks.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1288</enrollment>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>Cohort</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Chronic kidney disease patients with anemia treated with Mircera
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients, &gt;/= 18 years of age

          -  Chronic kidney disease in predialysis (stage 3 and 4) and dialysis

          -  Renal anemia treated with Mircera according to label for at least 9 months before date
             of signed informed consent

        Exclusion Criteria:

          -  Participation in an interventional clinical trial within the retrospective observation
             period

          -  Contraindications to Mircera administration as per label or judged by the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>General Hospital of Artas; Nephrology</name>
      <address>
        <city>Arta</city>
        <zip>47100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Attikon Center; Nephrology</name>
      <address>
        <city>Athens</city>
        <zip>11362</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Athinaiki Private Clinic</name>
      <address>
        <city>Athens</city>
        <zip>11521</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital henry dunant; Nephrology</name>
      <address>
        <city>Athens</city>
        <zip>11526</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Hippokration of Athens; Nephrology</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Of Athens G.Gennimatas; Nephrology</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyanos Stavros Private Hospital; Nephrologic Clinic</name>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Of West Attikis; Nephrology</name>
      <address>
        <city>Athens</city>
        <zip>12351</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Attikon ; Pathology Clinic</name>
      <address>
        <city>Athens</city>
        <zip>124 61</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iaso General Private Clinic; Nephrology</name>
      <address>
        <city>Athens</city>
        <zip>15562</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Agia Olga; Nephrology</name>
      <address>
        <city>Athen</city>
        <zip>14233</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iatriko Athinon Clinic Dafnis; Nephrology Department</name>
      <address>
        <city>Daphni-athens</city>
        <zip>17237</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Of Dramas; Dialysis Center Unit</name>
      <address>
        <city>Drama</city>
        <zip>66100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Timios Stavros Clinic; Nephrology Department</name>
      <address>
        <city>Egaleo</city>
        <zip>12244</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Of Heraklion; Nefrologiki Clinic</name>
      <address>
        <city>Heraklion</city>
        <zip>71110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Of Katerinis; Nephrology Unit</name>
      <address>
        <city>Katerini</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Of Lamias; Nephrology</name>
      <address>
        <city>Lamia</city>
        <zip>35100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univeristy Hospital of Larissa; Nephrology</name>
      <address>
        <city>Larissa</city>
        <zip>41 110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eytychios Patsidis Center Of Haemodialysis</name>
      <address>
        <city>Larissa</city>
        <zip>41335</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leivadia General Hospital; Nephrologic Clinic</name>
      <address>
        <city>Leivadia</city>
        <zip>32100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Of Leykadas; Dialysis Center Unit</name>
      <address>
        <city>Leykada</city>
        <zip>31100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyanous Stavros of Patras, Renal Disease Therapy Unit</name>
      <address>
        <city>Patra</city>
        <zip>26225</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Olympion Therapeytirion; Nefrology</name>
      <address>
        <city>Patra</city>
        <zip>26443</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Tzanio ; Nephrology</name>
      <address>
        <city>Piraeus</city>
        <zip>18536</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Of Chalkidikis; Dialysis Center Unit</name>
      <address>
        <city>Polygyros</city>
        <zip>63100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rodos General Hospital; Nephrologic Clinic</name>
      <address>
        <city>Rhodes</city>
        <zip>85100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alpha Nephrodynamiki Of Serres; Dialysis Center Unit</name>
      <address>
        <city>Serres</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ahepa Hospital; 1St Dept. of Medicine</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54636</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IPPOKRATES Private Dialysis Centre</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54643</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Of Thessalonikis Papageorgiou; Nephrology</name>
      <address>
        <city>Thessaloniki</city>
        <zip>56403</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alfa Nefrodynamiki; Nefrology</name>
      <address>
        <city>Thessaloniki</city>
        <zip>57500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thessaliki Nossileytiki; Nephrology</name>
      <address>
        <city>Volos</city>
        <zip>38221</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Volos; Nephrology</name>
      <address>
        <city>Volos</city>
        <zip>38222</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2011</study_first_submitted>
  <study_first_submitted_qc>May 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2011</study_first_posted>
  <results_first_submitted>November 23, 2015</results_first_submitted>
  <results_first_submitted_qc>November 23, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 28, 2015</results_first_posted>
  <last_update_submitted>June 13, 2017</last_update_submitted>
  <last_update_submitted_qc>June 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Mircera</title>
          <description>Participants with renal anemia due to chronic kidney disease (CKD) in pre-dialysis (Stage 3-4) and dialysis (Stage 5) were treated with Mircera according to the label for at least 9 months. This non-interventional study did not affect by any means the treatment, medical care or monitoring of the participant, since it reported 9-month retrospective data, which already existed in the participantsâ medical files.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1288"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="1285"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1283"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Enrolled, but not treated</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Dose data not recorded</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analysis population included all treated participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Mircera</title>
          <description>Participants with renal anemia due to chronic kidney disease (CKD) in pre-dialysis (Stage 3-4) and dialysis (Stage 5) were treated with Mircera according to the label for at least 9 months. This non-interventional study did not affect by any means the treatment, medical care or monitoring of the participant, since it reported 9-month retrospective data, which already existed in the participantsâ medical files.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1285"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Data for this baseline characteristic were available for 1276 participants only.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.13" spread="13.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="570"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="715"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least One Hemoglobin Cycling</title>
        <description>Hemoglobin cycling was defined as 1 or more cycles of oscillation in hemoglobin with an amplitude of greater than or equal to (&gt;=) 1.5 gram per deciliter (g/dL) and a duration &gt;=8 weeks.</description>
        <time_frame>9 months</time_frame>
        <population>Analysis population included all treated participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Mircera</title>
            <description>Participants with renal anemia due to chronic kidney disease (CKD) in pre-dialysis (Stage 3-4) and dialysis (Stage 5) were treated with Mircera according to the label for at least 9 months. This non-interventional study did not affect by any means the treatment, medical care or monitoring of the participant, since it reported 9-month retrospective data, which already existed in the participantsâ medical files.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least One Hemoglobin Cycling</title>
          <description>Hemoglobin cycling was defined as 1 or more cycles of oscillation in hemoglobin with an amplitude of greater than or equal to (&gt;=) 1.5 gram per deciliter (g/dL) and a duration &gt;=8 weeks.</description>
          <population>Analysis population included all treated participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1285"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Full Hemoglobin Cycles Per Participant</title>
        <description>Hemoglobin cycling was defined as 1 or more cycles of oscillation in hemoglobin with an amplitude of &gt;=1.5 g/dL and a duration &gt;=8 weeks.</description>
        <time_frame>9 months</time_frame>
        <population>Analysis population included all treated participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Mircera</title>
            <description>Participants with renal anemia due to chronic kidney disease (CKD) in pre-dialysis (Stage 3-4) and dialysis (Stage 5) were treated with Mircera according to the label for at least 9 months. This non-interventional study did not affect by any means the treatment, medical care or monitoring of the participant, since it reported 9-month retrospective data, which already existed in the participantsâ medical files.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Full Hemoglobin Cycles Per Participant</title>
          <description>Hemoglobin cycling was defined as 1 or more cycles of oscillation in hemoglobin with an amplitude of &gt;=1.5 g/dL and a duration &gt;=8 weeks.</description>
          <population>Analysis population included all treated participants.</population>
          <units>cycles</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1285"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.38" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Type 2 Diabetes Who Experienced at Least 1 Hemoglobin Cycling</title>
        <description>Hemoglobin cycling was defined as 1 or more cycles of oscillation in hemoglobin with an amplitude of &gt;=1.5 g/dL and a duration &gt;=8 weeks.</description>
        <time_frame>9 months</time_frame>
        <population>Analysis population included all treated participants. 'N' (number of participants analyzed) included those participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Mircera</title>
            <description>Participants with renal anemia due to chronic kidney disease (CKD) in pre-dialysis (Stage 3-4) and dialysis (Stage 5) were treated with Mircera according to the label for at least 9 months. This non-interventional study did not affect by any means the treatment, medical care or monitoring of the participant, since it reported 9-month retrospective data, which already existed in the participantsâ medical files.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Type 2 Diabetes Who Experienced at Least 1 Hemoglobin Cycling</title>
          <description>Hemoglobin cycling was defined as 1 or more cycles of oscillation in hemoglobin with an amplitude of &gt;=1.5 g/dL and a duration &gt;=8 weeks.</description>
          <population>Analysis population included all treated participants. 'N' (number of participants analyzed) included those participants who were evaluable for this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Due to 'retrospective' nature of this registry data study, it was not possible to collect complete adverse events (AE) data. Hence, it was planned not to collect any AE data in this study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Mircera</title>
          <description>Participants with renal anemia due to chronic kidney disease (CKD) in pre-dialysis (Stage 3-4) and dialysis (Stage 5) were treated with Mircera according to the label for at least 9 months. This non-interventional study did not affect by any means the treatment, medical care or monitoring of the participant, since it reported 9-month retrospective data, which already existed in the participantsâ medical files.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffmann-LaRoche</organization>
      <phone>800-821-8590</phone>
      <email>genentech@druginfo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

